J.P. Morgan has reiterated its 'Overweight' rating on Galderma, citing strong top-line growth, particularly from Nemluvio sales, and strategic benefits from the ZO Skin Health acquisition. This analyst endorsement suggests continued positive sentiment and potential for stock appreciation for Galderma.
J.P. Morgan analysts reaffirmed their 'Overweight' rating on Galderma, a Swiss dermatology company, on October 28, 2026. This positive outlook is driven by Galderma's robust top-line growth, particularly the continued sales momentum of its drug Nemluvio, and the strategic advantages gained from the acquisition of ZO Skin Health. This analyst endorsement is significant for Galderma as it signals continued confidence from a major investment bank, potentially attracting more investor interest and supporting its stock price in the short to medium term. For traders, this presents an opportunity to consider long positions in Galderma, though the impact is moderate as it's a reaffirmation rather than a new rating.